Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus

Intersect ENT (NASDAQ: XENT) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $32.8 million versus the consensus estimate of $32.5 million.

GUIDANCE:

Intersect ENT sees Q1 2019 revenue of $26-26.5 million, versus the consensus of $27.5 million.

Intersect ENT sees FY2019 revenue of $123-127 million, versus the consensus of $127.24 million.

Outlook

Intersect ENT continues to forecast 2019 revenue in the range of $123 to $127 million and first quarter revenue in the range of $26.0 to $26.5 million. The Company’s 2019 outlook for gross margin is in the range of 80-81% and for expenses in the range of $135 to $137 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c